Tesaro (United States)

Recent papers from Tesaro (United States)

1. Causal, stable and homogeneous formulas for acoustic and ultrasonic propagation through atmosphereWaves in Random and Complex Media · 2025
2. Vaginal Packing After Pelvic Floor Reconstructive Surgery: Does the Soaking Agent Used for Packing (Bupivacaine, Estrogen or Saline) Impact Postoperative Pain Scores?Journal of Minimally Invasive Gynecology · 2024
3. Monitoring Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Using Circulating Tumor DNA2024
4. Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast CancerJCO Precision Oncology · 2022
5. Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient StratificationCancer Research · 2022
6. Sample size calculation for recurrent event data with additive rates modelsPharmaceutical Statistics · 2021
7. Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) ApoenzymeJournal of Medicinal Chemistry · 2021
8. Some new confidence intervals for Kaplan‐Meier based estimators from one and two sample survival dataStatistics in Medicine · 2021
9. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazardsStatistical Methods in Medical Research · 2021
10. Power and sample size forGEEanalysis of incomplete paired outcomes in 2 × 2 crossover trialsPharmaceutical Statistics · 2021
11. Score confidence intervals and sample sizes for stratified comparisons of binomial proportionsStatistics in Medicine · 2020
12. Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1RJournal of Medicinal Chemistry · 2020
13. An Improved Sample Size Calculation Method for Score Tests in Generalized Linear ModelsStatistics in Biopharmaceutical Research · 2020
14. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancerTyöväentutkimus Vuosikirja · 2020
15. ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patientsEuropean Journal of Cancer · 2020
16. Real-World Adverse Events with Niraparib 200 mg/Day Maintenance Therapy in Ovarian Cancer: A Retrospective StudyFuture Oncology · 2019
17. Niraparib in Patients with Newly Diagnosed Advanced Ovarian CancerNew England Journal of Medicine · 2019
18. Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA TrialJournal of Clinical Oncology · 2019
19. Phase I Pharmacokinetic Study of Niraparib in Chinese Patients with Epithelial Ovarian CancerThe Oncologist · 2019
20. Sample size calculation for the Andersen‐Gill model comparing rates of recurrent eventsStatistics in Medicine · 2019